XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 29.81

-4.1%

Dec 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (16143)	12/23/2002 5:21:01 PM
From: Arthur Radley	Read Replies (2) of 17367

After such a long wait....XOMA has some positive news.... Welcome, PrintedWords [Sign Out] Money Manager - My Yahoo! View - Customize Financial News Enter symbol(s) BasicDayWatchPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup Press Release Source: Genentech Genentech and XOMA Submit Biologics License Application for FDA Approval of Raptiva -- Efalizumab -- for the Treatment of Moderate-to-Severe Plaque Psoriasis Monday December 23, 4:30 pm ET SOUTH SAN FRANCISCO, Calif. & BERKELEY, Calif.--(BUSINESS WIRE)--Dec. 23, 2002--Genentech, Inc. (NYSE: DNA - News) and XOMA Ltd. (Nasdaq: XOMA - News) today announced they have submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Raptiva(TM) (Efalizumab), a recombinant humanized monoclonal antibody under evaluation for the treatment of moderate-to-severe plaque psoriasis.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next